Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Primary Myelofibrosis 13 Myeloproliferative Disorders 9 Leukemia, Myeloid, Acute 8 Thrombocythemia, Essential 6 Polycythemia Vera 6 Myelodysplastic Syndromes 5 Lymphoma, T-Cell 4 Leukemia 4 Recurrence 3 Neoplasms 3 Graft vs Host Disease 3 Myelodysplastic-Myeloproliferative Diseases 2 Lymphoma, T-Cell, Cutaneous 2 Lymphoma 2 Leukemia, Prolymphocytic, T-Cell 2 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2 Hematologic Neoplasms 2 Uveal Melanoma 1 Thalassemia 1 Targeted Therapy 1 Prostatic Neoplasms 1 Preleukemia 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Precancerous Conditions 1 Neoplasms by Histologic Type 1 Mycosis Fungoides 1 Multiple Myeloma 1 Mesothelioma 1 Melanoma 1 Lymphoma, T-Cell, Peripheral 1

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Exanthema × ruxolitinib × 90 days × Clear all

NCT06399029 2026-04-30

TRUX-LST

University of Zurich

Phase 2 Active not recruiting

Exanthema

Data powered by HemOnc (CC BY 4.0) Colophon ⚡